Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

BAX 855 success in Phase III trial for Haemophilia A prophylaxis- Baxter

22-Aug-2014

Baxter International Inc. announced ...

FDA approves Arnuity Ellipta for treatment of Asthma- GSK

22-Aug-2014

GlaxoSmithKline plc announced that ...

Eisai files Fycompa at EMA and FDA for uncontrolled primary generalized Tonic-Clonic Seizures.

22-Aug-2014

Eisai has filed its anti-epileptic ...

Ixekizumab superior to etanercept in Phase III trials for plaque Psoriasis- Eli Lilly

22-Aug-2014

Eli Lilly and Company's ...

NICE recommends Revlimid for specific Myelodysplastic syndromes- Celgene

21-Aug-2014

In new final draft guidance, the ...

Boehringer files NDA at FDA for olodaterol + tiotropium for COPD.

21-Aug-2014

Boehringer Ingelheim has announced ...

Migalastat success in Phase III (Study 012) for treatment of Fabry disease- Amicus Therapeutics

21-Aug-2014

Amicus Therapeutics announced ...

Recent Updates

Drugs

Clinical Guidelines

Treatment of primary breast cancer

British Guideline on the Management of Asthma

Good clinical practice guidelines for care home residents with diabetes

Guidelines on the diagnosis and management of heparin induced thrombocytopenia: second edition

Medical Journals

Polymorphism M55V in gene encoding small ubiquitin-like modifier 4 (SUMO4) protein associates with susceptibility to type 1 (and type 2) diabetes

Feeding difficulties in children with esophageal atresia: treatment by a multidisciplinary team

Airway and systemic inflammation in obese children with asthma

Antimalarial evaluation and docking studies of hybrid phenylthiazolyl-1,3,5-triazine derivatives: A novel and potential antifolate lead for Pf-DHFR-TS inhibition

epgonline.org Social